top of page
Patient Reported Outcomes Validity and Valuation
Saturday, December 5th: 7:00 – 9:30 pm Stayed logged on following the Keynote lecture, to hear this exciting session on patient-reported...
Pauline Lavigne
Nov 22, 20202 min read
Patient Engagement is More Than a Catchphrase: One Patient Does Not Engagement Make
Saturday, December 5th: 4:00 – 6:00 pm We have all been increasingly hearing about the need to include patient representatives in our...
Pauline Lavigne
Nov 22, 20202 min read
Understanding the Results of SGLT2 Inhibitors Heart Failure Trials
Saturday, December 5th: 1:30 – 3:30 pm Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel oral antidiabetic drugs to lower...
Pauline Lavigne
Nov 21, 20202 min read
Evidence Generation in Food and Diet Health Science: Parts 1 and 2
Friday, December 4th: 4:00 – 6:30 pm and 7:00 – 9:00 pm We hear a lot about “heart health foods”, but what does that mean and what...
Pauline Lavigne
Nov 21, 20202 min read
How will the removal of requirement for CVOTs from FDA shape the future of trial design?
Friday, December 4th: 1:30 – 3:30 pm How will the removal of requirement for cardiovascular outcome trials (CVOTs) from the 2020 FDA...
Pauline Lavigne
Nov 21, 20202 min read
Operational Shifts in Trial Conduct: Lessons Learnt From The COVID-19 Crisis
Friday, December 4th: 7:00 – 9:00 pm The COVID-19 pandemic has affected almost every aspect of daily life for the majority of people on...
Pauline Lavigne
Nov 21, 20202 min read
CVCT-WOMEN AS ONE : Evidence Gaps in Women's CV Health and How to Improve Women's Leadership
Friday, December 4th: 1:30 – 3:30 pm and 4:00 – 6:30 pm A frequently underserved population in cardiovascular medicine is a large one…...
Pauline Lavigne
Nov 20, 20202 min read
Understanding and Interpreting the Results of Mineralocorticoid Receptor Antagonists Trials
Friday, December 4th: 4:00 – 6:00 pm Understanding and Interpreting the Results of Mineralocorticoid Receptor Antagonists (MRA) Trials in...
Pauline Lavigne
Nov 20, 20202 min read
FIDELIO Trial in Context
Friday December 4th: 7:00 – 9:00 pm Is finerenone the answer for all our patients with diabetic kidney disease (DKD), is FIDELIO the last...
Pauline Lavigne
Nov 20, 20202 min read
The Value of Biomarkers in Trials
Friday, December 4th: 1:30 – 3:30 pm The use of biomarkers in cardiovascular medicine is fraught with controversy. While clinicians and...
Pauline Lavigne
Nov 20, 20201 min read
NASH and Obesity Trials: Parts 1 and 2
Thursday, December 3rd: 5:30 – 7:30 pm and 8:00 – 9:30 pm Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic...
Pauline Lavigne
Nov 19, 20202 min read
The Transformation of Trial Conduct Post-COVID. How to Keep the Best?
Thursday, December 3rd: 3:30 – 5:30 pm The COVID-19 pandemic has important implications for the safety of participants in clinical...
Pauline Lavigne
Nov 19, 20202 min read
How Will the HFrEF Therapy Landscape Change?
Thursday, December 3rd: 1:30 – 3:00 pm Heart failure (HF) remains one of our most challenging CV diseases, to diagnose, to treat, and to...
Pauline Lavigne
Nov 19, 20201 min read
Electrophysiology: Parts 1 and 2
Thursday, December 3rd: 1:30 – 3:30 pm and 4:00 – 5:30 pm I know what you are thinking. Electrophysiology is old, and boring, and you...
Pauline Lavigne
Nov 18, 20203 min read
SGLT2i: Trials in CKD
Understanding and Interpreting the Results of SGLT2i Trials in CKD Thursday, December 3rd: 7:30 – 9:00 pm Sodium-glucose cotransporter 2...
Pauline Lavigne
Nov 18, 20202 min read
Data Science and Information Technology Revolutionizing Clinical Trials
Thursday, December 3rd: 5:30 – 7:30 pm Artificial Intelligence, Machine Learning, Data Science… Are they here or are they still just...
Pauline Lavigne
Nov 18, 20202 min read
bottom of page